GRM1 and cancer: In addition to overexpression, mutations and single nucleotide polymorphisms or SNPs of GRM1 have been identified in multiple cancers, such as prostate (145), colorectal, and lung (146), that led to alterations in receptor activation, intracellular localization, and downstream signaling.